Old Web
English
Sign In
Acemap
>
authorDetail
>
Soichiro Hata
Soichiro Hata
Hokkaido University
Pancreatic cancer
KRAS
Biology
Cancer research
Fibrosis
4
Papers
35
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
2021
Cell Communication and Signaling
Ari Hashimoto
Haruka Handa
Soichiro Hata
Akio Tsutaho
Takao Yoshida
Satoshi Hirano
Shigeru Hashimoto
Hisataka Sabe
Show All
Source
Cite
Save
Citations (1)
Angiotensin-converting enzyme inhibitor prevents skeletal muscle fibrosis in diabetic mice.
2021
Experimental Physiology
Naoya Kakutani
Shingo Takada
Hideo Nambu
Satoshi Maekawa
Hikaru Hagiwara
Katsuma Yamanashi
Yoshikuni Obata
Ippei Nakano
Yoshizuki Fumoto
Soichiro Hata
Takaaki Furihata
Arata Fukushima
Takashi Yokota
Shintaro Kinugawa
Show All
Source
Cite
Save
Citations (0)
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
2020
Cell Communication and Signaling
Akio Tsutaho
Ari Hashimoto
Shigeru Hashimoto
Soichiro Hata
Shion Kachi
Satoshi Hirano
Hisataka Sabe
Show All
Source
Cite
Save
Citations (4)
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
2019
Proceedings of the National Academy of Sciences of the United States of America
Shigeru Hashimoto
Shotaro Furukawa
Ari Hashimoto
Akio Tsutaho
Akira Fukao
Yurika Sakamura
Gyanu Parajuli
Yasuhito Onodera
Yutaro Otsuka
Haruka Handa
Tsukasa Oikawa
Soichiro Hata
Yoshihiro Nishikawa
Yusuke Mizukami
Yuzo Kodama
Masaaki Murakami
Toshinobu Fujiwara
Satoshi Hirano
Hisataka Sabe
Show All
Source
Cite
Save
Citations (30)
1